Form 4: UNITED THERAPEUTICS Executive Sells Shares
Insider Transaction (Form 4)
Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 8,300 Common Stock at $146.03 ($1,212,049) on September 17, 2026; holds 53,472 after (Direct).
- Open-market sale: disposed of 1,579 Common Stock at $495.97 ($783,132) on September 17, 2026; holds 51,893 after (Direct).
- Open-market sale: disposed of 2,873 Common Stock at $496.58 ($1,426,662) on September 17, 2026; holds 49,020 after (Direct).
- Open-market sale: disposed of 1,400 Common Stock at $497.54 ($696,561) on September 17, 2026; holds 47,620 after (Direct).
- Open-market sale: disposed of 843 Common Stock at $498.74 ($420,435) on September 17, 2026; holds 46,777 after (Direct).
- Open-market sale: disposed of 1,160 Common Stock at $499.75 ($579,712) on September 17, 2026; holds 45,617 after (Direct).
- Open-market sale: disposed of 125 Common Stock at $500.80 ($62,600) on September 17, 2026; holds 45,492 after (Direct).
- Open-market sale: disposed of 320 Common Stock at $501.58 ($160,506) on September 17, 2026; holds 45,172 after (Direct).
- Option exercise/conversion: disposed of 8,300 Stock Option on September 17, 2026; holds 47,540 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,129,608 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul A Mahon — Officer (EVP & GENERAL COUNSEL)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 8,300 | $146 | $1.2M | 53,472 |
| 2026-09-17 | Open-market sale | Common Stock | 1,579 | $496 | $783.1K | 51,893 |
| 2026-09-17 | Open-market sale | Common Stock | 2,873 | $497 | $1.4M | 49,020 |
| 2026-09-17 | Open-market sale | Common Stock | 1,400 | $498 | $696.6K | 47,620 |
| 2026-09-17 | Open-market sale | Common Stock | 843 | $499 | $420.4K | 46,777 |
| 2026-09-17 | Open-market sale | Common Stock | 1,160 | $500 | $579.7K | 45,617 |
| 2026-09-17 | Open-market sale | Common Stock | 125 | $501 | $62.6K | 45,492 |
| 2026-09-17 | Open-market sale | Common Stock | 320 | $502 | $160.5K | 45,172 |
| 2026-09-17 | Option exercise/conversion | Stock Option | 8,300 | — | — | 47,540 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (8,300 shares) |
| 2026-09-17 | Open-market sale (1,579 shares) |
| 2026-09-17 | Open-market sale (2,873 shares) |
| 2026-09-17 | Open-market sale (1,400 shares) |
| 2026-09-17 | Open-market sale (843 shares) |
| 2026-09-17 | Open-market sale (1,160 shares) |
| 2026-09-17 | Open-market sale (125 shares) |
| 2026-09-17 | Open-market sale (320 shares) |
| 2026-09-17 | Option exercise/conversion (8,300 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.